COMMUNIQUÉS West-GlobeNewswire

Novo Nordisk reports up to 13.8% weight loss in people with obesity receiving semaglutide in phase 2 trial
23/06/2017
Bagsværd, Denmark, 23 June 2017 - Novo Nordisk today announced the headline results from a 52-week double-blind phase 2 clinical trial with once-daily subcutaneous semaglutide investigating safety and potential for [...]
SHIRE TO PRESENT NEW DATA AT ISTH 2017 TO ADVANCE THE STANDARD OF CARE IN HEMOPHILIA
23/06/2017
More than 35 presentations and sessions showcase Shire's gene therapy pipeline and leading factor portfolio Zug, Switzerland - June 23, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), a leading biotechnology company focused [...]
Novo Nordisk A/S: CHMP adopts positive opinion for EU label update of Victoza® based on the LEADER trial
23/06/2017
Bagsværd, Denmark, 23 June 2017 - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), has issued a positive opinion on update of the EU [...]
uniQure Announces Clinical Data Presentations at the Upcoming International Society on Thrombosis and Hemostasis (ISTH) Congress
23/06/2017
~ Updated, Long-term Results from the Phase I/II Dose-Escalating Study of AMT-060 to be Presented on Monday, July 10, 2017 ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 23, 2017 (GLOBE NEWSWIRE) -- uniQure N.V [...]
Medtronic Announces 7 Percent Increase in Cash Dividend
23/06/2017
40th Consecutive Year of Dividend Increases; Board Authorizes $5 Billion for Share Repurchases DUBLIN - June 23, 2017 - The board of directors of Medtronic plc (NYSE: MDT) today approved a 7 percent increase in its [...]
Novartis Kisqali® (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor
23/06/2017
CHMP opinion based on pivotal Phase III trial that showed Kisqali plus letrozole reduced risk of disease progression or death by 44% over letrozole alone among postmenopausal women with HR+/HER2- advanced breast cancer[ [...]
Novartis data shows half of eligible Ph+ CML-CP patients remain in Treatment-free Remission nearly two years after stopping Tasigna®
23/06/2017
New 96-week data support durability and safety of Treatment-free Remission (TFR) in Ph+ CML-CP patients who stop taking Tasigna [1,2] More than 90% of Ph+ CML-CP patients in ENESTfreedom and ENESTop who stopped Tasigna [...]
Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL
23/06/2017
83% of patients achieved complete remission (CR) or CR with incomplete blood count recovery within 3 months of treatment with CTL019; consistent with interim ELIANA data Data evaluating 63 patients demonstrate relapse- [...]
Virbac :Sébastien Huron deviendra le président du directoire du groupe Virbac fin 2017
23/06/2017
Sébastien Huron deviendra le président du directoire du groupe Virbac fin 2017 Carros, France - Le 23 juin 2017 Virbac annonce l'intention du conseil de surveillance de nommer Sébastien Huron président du directoire de [...]
Virbac : Sébastien Huron will become the new chairman of the executive board as of December 2017
23/06/2017
Virbac group: Sébastien Huron will become the new chairman of the executive board as of December 2017 Carros, France - June 23, 2017 Virbac has announced the supervisory board's intention to appoint Sébastien Huron as [...]
GENFIT franchit une étape décisive pour le développement d'un test de diagnostic in-vitro (IVD) non-invasif dans la NASH
23/06/2017
GENFIT franchit une étape décisive pour le développement d'un test de diagnostic in-vitro (IVD) non-invasif dans la NASH Achèvement de la phase de faisabilité du programme de biomarqueurs dans la NASH après confirmation [...]
GENFIT Reaches a Critical Milestone towards the Development of a Non-Invasive In Vitro Diagnostic (IVD) Test for NASH
23/06/2017
GENFIT Reaches a Critical Milestone towards the Development of a Non-Invasive In Vitro Diagnostic (IVD) Test for NASH Completion of the NASH biomarker program feasibility phase, after confirmation of the competitive [...]
DiaSorin and Tecan to collaborate in new platform development
23/06/2017
Saluggia, Italy and Männedorf, Switzerland, June 23, 2017 - DiaSorin (FTSE Italy Mid Cap: DIA) and Tecan Group (SIX Swiss Exchange: TECN) announced today that they have agreed to collaborate in a development under which [...]
TiGenix to present at the 7th TERMIS-EU Conference in Davos, Switzerland
23/06/2017
PRESS RELEASE TiGenix to present at the 7 th TERMIS-EU Conference in Davos, Switzerland Leuven (BELGIUM) - June 23, 2017, 07:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical [...]
Présentation de TiGenix à l'occasion de la 7ème Conférence TERMIS-UE à Davos (Suisse)
23/06/2017
COMMUNIQUÉ DE PRESSE Présentation de TiGenix à l'occasion de la 7 ème Conférence TERMIS-UE à Davos (Suisse) Louvain (BELGIQUE) - vendredi 23 juin 2017, 07h. CEST - TiGenix NV (Euronext Brussels et NASDAQ : TIG), société [...]
Addex Shareholders Approved all Board Proposals at 2017 Annual General Meeting
23/06/2017
Roger Mills elected to the Addex Board of Directors Geneva, Switzerland, 23 June 2017 - Addex Therapeutics (SIX: ADXN), announced today that its shareholders approved all the proposals of the board of directors at its [...]
Novartis combination targeted therapy Tafinlar® + Mekinist® receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC)
22/06/2017
Approval provides first targeted treatment in the US specifically for BRAF V600E mutation-positive metastatic NSCLC More than 60% of treatment-naïve and previously treated patients with BRAF V600E mutant metastatic [...]
Targovax ASA: Mandatory notification of trade by primary insider in relation to exercise of employee options
22/06/2017
1. Exercise of employee share options Berit Iversen, VP CMC of Targovax (the "Primary Insider"), has on 22 June 2017 subscribed for 25,000 shares in Targovax ASA at a price of NOK 7.5 per share in connection with her [...]
Novo Nordisk A/S: CHMP endorses EU label update of Saxenda® based on the LEADER trial
22/06/2017
PR170622_LEADER_EU_CHMP_Saxenda_UK This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely [...]

Pages